Rigel Pharmaceuticals, Inc. (RIGL)
USD 19.36
(3.42%)
USD 19.36
(3.42%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 145.86 Million USD | -1.37% |
| 2022 | 147.89 Million USD | 7.99% |
| 2021 | 136.95 Million USD | 79.37% |
| 2020 | 76.35 Million USD | -18.56% |
| 2019 | 93.75 Million USD | 220.72% |
| 2018 | 29.23 Million USD | 58.31% |
| 2017 | 18.46 Million USD | -20.09% |
| 2016 | 23.1 Million USD | -42.76% |
| 2015 | 40.36 Million USD | 55.92% |
| 2014 | 25.88 Million USD | 45.39% |
| 2013 | 17.8 Million USD | -14.99% |
| 2012 | 20.94 Million USD | -0.05% |
| 2011 | 20.95 Million USD | 1.91% |
| 2010 | 20.56 Million USD | -33.4% |
| 2009 | 30.87 Million USD | -22.21% |
| 2008 | 39.69 Million USD | 18.11% |
| 2007 | 33.6 Million USD | 29.2% |
| 2006 | 26.01 Million USD | -33.44% |
| 2005 | 39.08 Million USD | 47.35% |
| 2004 | 26.52 Million USD | 70.54% |
| 2003 | 15.55 Million USD | -17.72% |
| 2002 | 18.9 Million USD | 7.96% |
| 2001 | 17.5 Million USD | 14.78% |
| 2000 | 15.25 Million USD | -7.07% |
| 1999 | 16.41 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 158.32 Million USD | 0.08% |
| 2024 Q1 | 158.19 Million USD | 8.45% |
| 2023 Q4 | 145.86 Million USD | -0.88% |
| 2023 Q2 | 145.2 Million USD | -1.8% |
| 2023 Q3 | 147.15 Million USD | 1.34% |
| 2023 Q1 | 147.86 Million USD | -0.02% |
| 2023 FY | 145.86 Million USD | -1.37% |
| 2022 Q4 | 147.89 Million USD | 9.19% |
| 2022 FY | 147.89 Million USD | 7.99% |
| 2022 Q3 | 135.44 Million USD | 2.86% |
| 2022 Q2 | 131.67 Million USD | -7.45% |
| 2022 Q1 | 142.27 Million USD | 3.89% |
| 2021 FY | 136.95 Million USD | 79.37% |
| 2021 Q1 | 137.69 Million USD | 80.34% |
| 2021 Q2 | 133.48 Million USD | -3.06% |
| 2021 Q3 | 136.84 Million USD | 2.52% |
| 2021 Q4 | 136.95 Million USD | 0.08% |
| 2020 Q4 | 76.35 Million USD | 5.89% |
| 2020 Q1 | 64.86 Million USD | -30.81% |
| 2020 Q3 | 72.1 Million USD | -3.64% |
| 2020 Q2 | 74.82 Million USD | 15.36% |
| 2020 FY | 76.35 Million USD | -18.56% |
| 2019 Q1 | 77.46 Million USD | 165.01% |
| 2019 FY | 93.75 Million USD | 220.72% |
| 2019 Q3 | 87.15 Million USD | 11.92% |
| 2019 Q4 | 93.75 Million USD | 7.58% |
| 2019 Q2 | 77.86 Million USD | 0.51% |
| 2018 Q3 | 19.69 Million USD | 11.58% |
| 2018 Q4 | 29.23 Million USD | 48.42% |
| 2018 FY | 29.23 Million USD | 58.31% |
| 2018 Q1 | 19 Million USD | 2.93% |
| 2018 Q2 | 17.65 Million USD | -7.12% |
| 2017 Q3 | 15.08 Million USD | -4.98% |
| 2017 FY | 18.46 Million USD | -20.09% |
| 2017 Q2 | 15.87 Million USD | -7.96% |
| 2017 Q1 | 17.24 Million USD | -25.37% |
| 2017 Q4 | 18.46 Million USD | 22.42% |
| 2016 FY | 23.1 Million USD | -42.76% |
| 2016 Q1 | 32.82 Million USD | -18.67% |
| 2016 Q3 | 22.69 Million USD | -11.34% |
| 2016 Q4 | 23.1 Million USD | 1.8% |
| 2016 Q2 | 25.6 Million USD | -22.02% |
| 2015 Q3 | 42.76 Million USD | -9.4% |
| 2015 Q4 | 40.36 Million USD | -5.61% |
| 2015 FY | 40.36 Million USD | 55.92% |
| 2015 Q1 | 53.54 Million USD | 106.81% |
| 2015 Q2 | 47.2 Million USD | -11.84% |
| 2014 FY | 25.88 Million USD | 45.39% |
| 2014 Q1 | 14.96 Million USD | -15.97% |
| 2014 Q4 | 25.88 Million USD | 58.16% |
| 2014 Q3 | 16.36 Million USD | -1.97% |
| 2014 Q2 | 16.69 Million USD | 11.6% |
| 2013 Q1 | 17.62 Million USD | -15.84% |
| 2013 FY | 17.8 Million USD | -14.99% |
| 2013 Q3 | 16.13 Million USD | -2.94% |
| 2013 Q4 | 17.8 Million USD | 10.36% |
| 2013 Q2 | 16.62 Million USD | -5.7% |
| 2012 FY | 20.94 Million USD | -0.05% |
| 2012 Q4 | 20.94 Million USD | 7.35% |
| 2012 Q3 | 19.51 Million USD | 4.85% |
| 2012 Q2 | 18.61 Million USD | 7.38% |
| 2012 Q1 | 17.33 Million USD | -17.3% |
| 2011 FY | 20.95 Million USD | 1.91% |
| 2011 Q3 | 17.9 Million USD | 4.18% |
| 2011 Q4 | 20.95 Million USD | 17.07% |
| 2011 Q2 | 17.18 Million USD | 5.04% |
| 2011 Q1 | 16.35 Million USD | -20.46% |
| 2010 Q1 | 124.36 Million USD | 302.76% |
| 2010 FY | 20.56 Million USD | -33.4% |
| 2010 Q4 | 20.56 Million USD | -6.95% |
| 2010 Q3 | 22.1 Million USD | -69.08% |
| 2010 Q2 | 71.47 Million USD | -42.52% |
| 2009 Q1 | 37.05 Million USD | -6.64% |
| 2009 Q4 | 30.87 Million USD | -9.15% |
| 2009 FY | 30.87 Million USD | -22.21% |
| 2009 Q3 | 33.98 Million USD | -7.31% |
| 2009 Q2 | 36.66 Million USD | -1.05% |
| 2008 Q2 | 32.47 Million USD | 14.27% |
| 2008 Q3 | 37.83 Million USD | 16.52% |
| 2008 Q4 | 39.69 Million USD | 4.91% |
| 2008 Q1 | 28.41 Million USD | -15.44% |
| 2008 FY | 39.69 Million USD | 18.11% |
| 2007 Q4 | 33.6 Million USD | 32.49% |
| 2007 FY | 33.6 Million USD | 29.2% |
| 2007 Q2 | 23.89 Million USD | -2.94% |
| 2007 Q1 | 24.62 Million USD | -5.34% |
| 2007 Q3 | 25.36 Million USD | 6.13% |
| 2006 FY | 26.01 Million USD | -33.44% |
| 2006 Q3 | 24.94 Million USD | -3.81% |
| 2006 Q2 | 25.93 Million USD | -25.23% |
| 2006 Q1 | 34.68 Million USD | -11.25% |
| 2006 Q4 | 26.01 Million USD | 4.28% |
| 2005 FY | 39.08 Million USD | 47.35% |
| 2005 Q4 | 39.08 Million USD | 21.6% |
| 2005 Q3 | 32.13 Million USD | -6.77% |
| 2005 Q2 | 34.47 Million USD | -3.14% |
| 2005 Q1 | 35.59 Million USD | 34.2% |
| 2004 FY | 26.52 Million USD | 70.54% |
| 2004 Q3 | 18.51 Million USD | 8.7% |
| 2004 Q4 | 26.52 Million USD | 43.27% |
| 2004 Q1 | 15.86 Million USD | 1.99% |
| 2004 Q2 | 17.03 Million USD | 7.38% |
| 2003 Q2 | 15 Million USD | -1.26% |
| 2003 Q3 | 15.75 Million USD | 5.01% |
| 2003 Q4 | 15.55 Million USD | -1.29% |
| 2003 Q1 | 15.19 Million USD | -19.61% |
| 2003 FY | 15.55 Million USD | -17.72% |
| 2002 Q2 | 21.48 Million USD | -2.04% |
| 2002 Q4 | 18.9 Million USD | -10.9% |
| 2002 FY | 18.9 Million USD | 7.96% |
| 2002 Q1 | 21.93 Million USD | 25.29% |
| 2002 Q3 | 21.21 Million USD | -1.27% |
| 2001 Q4 | 17.5 Million USD | -5.7% |
| 2001 Q3 | 18.56 Million USD | 33.92% |
| 2001 FY | 17.5 Million USD | 14.78% |
| 2001 Q1 | 14.54 Million USD | -4.66% |
| 2001 Q2 | 13.86 Million USD | -4.66% |
| 2000 Q4 | 15.25 Million USD | 0.0% |
| 2000 FY | 15.25 Million USD | -7.07% |
| 1999 FY | 16.41 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Absci Corporation | 58.3 Million USD | -150.187% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 58.66% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 96.399% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -4421.986% |
| Apollomics, Inc. | 14.15 Million USD | -930.658% |
| 180 Life Sciences Corp. | 5.38 Million USD | -2607.691% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -2685.886% |
| Bicycle Therapeutics plc | 224.41 Million USD | 34.999% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -430.221% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -12.026% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -185.441% |
| Chimerix, Inc. | 19.74 Million USD | -638.764% |
| CRISPR Therapeutics AG | 346.76 Million USD | 57.935% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 26.448% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -64.154% |
| Fortress Biotech, Inc. | 165.93 Million USD | 12.095% |
| Fortress Biotech, Inc. | 165.93 Million USD | 12.095% |
| Gritstone bio, Inc. | 125.91 Million USD | -15.844% |
| Allakos Inc. | 74.79 Million USD | -95.03% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 43.236% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -112.145% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 87.951% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -907.87% |
| Innoviva, Inc. | 568.55 Million USD | 74.344% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -20591.137% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1265.789% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -454.762% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -11127.247% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -1009.27% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -492.819% |
| ImmuCell Corporation | 18.81 Million USD | -675.279% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -416.789% |
| Incyte Corporation | 1.59 Billion USD | 90.839% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -162.377% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -36014.412% |
| Mustang Bio, Inc. | 17.61 Million USD | -727.907% |
| MiMedx Group, Inc. | 96.33 Million USD | -51.426% |
| MEI Pharma, Inc. | 8.35 Million USD | -1645.889% |
| MacroGenics, Inc. | 154.2 Million USD | 5.407% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -8200.306% |
| Mereo BioPharma Group plc | 15.96 Million USD | -813.852% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -4643.942% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | 5.368% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 79.089% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -70.891% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -2292.864% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -2788.495% |
| NextCure, Inc. | 14.99 Million USD | -872.655% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -436.895% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -3508.832% |
| Onconetix, Inc. | 23.18 Million USD | -529.264% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -2084.649% |
| Opthea Limited | 264.6 Million USD | 44.872% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -159.415% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -1105.061% |
| PDS Biotechnology Corporation | 33.25 Million USD | -338.583% |
| Precigen, Inc. | 41.64 Million USD | -250.276% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -1123.528% |
| Prime Medicine, Inc. | 60.78 Million USD | -139.995% |
| PureTech Health plc | 125.58 Million USD | -16.153% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -97.743% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 97.948% |
| Replimune Group, Inc. | 113.21 Million USD | -28.844% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -2521.236% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -4033.57% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 44.409% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -2107.702% |
| Sesen Bio, Inc. | 30.98 Million USD | -370.788% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -76.955% |
| Solid Biosciences Inc. | 38.45 Million USD | -279.294% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -148.567% |
| SciSparc Ltd. | 1.59 Million USD | -9045.392% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 54.57% |
| TG Therapeutics, Inc. | 169.08 Million USD | 13.73% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -198.106% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -10001.731% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 75.197% |
| UroGen Pharma Ltd. | 243.52 Million USD | 40.101% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -135.904% |
| XOMA Corporation | 145.58 Million USD | -0.199% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -17.036% |
| AbCellera Biologics Inc. | 335.77 Million USD | 56.558% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -1392.419% |
| Cassava Sciences, Inc. | 14.19 Million USD | -927.608% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -314.67% |
| Precision BioSciences, Inc. | 140.92 Million USD | -3.512% |
| Dyadic International, Inc. | 2.34 Million USD | -6131.984% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -3429.373% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -796.938% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -1529.821% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -369.168% |
| IGM Biosciences, Inc. | 220.17 Million USD | 33.749% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -51.696% |
| Acelyrin, Inc. | 86.35 Million USD | -68.922% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -196.626% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -11.6% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -4033.759% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | 3.327% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | 3.724% |
| Senti Biosciences, Inc. | 52.57 Million USD | -177.47% |
| Mesoblast Limited | 188.79 Million USD | 22.738% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | 19.315% |
| ChromaDex Corporation | 26.5 Million USD | -450.283% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1604.636% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 46.428% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -8884.206% |
| Seer, Inc. | 39.36 Million USD | -270.555% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 58.033% |
| Novavax, Inc. | 2.57 Billion USD | 94.329% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -1795.874% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -5.856% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -691.691% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -53.422% |
| Celcuity Inc. | 51.45 Million USD | -183.516% |
| ContextLogic Inc. | 206 Million USD | 29.19% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 70.023% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -104.07% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 98.095% |
| Amarin Corporation plc | 279.58 Million USD | 47.827% |
| AnaptysBio, Inc. | 364.28 Million USD | 59.958% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -1055.764% |
| Aptorum Group Limited | 5.25 Million USD | -2674.896% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 80.426% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 69.508% |
| Ardelyx, Inc. | 130.76 Million USD | -11.552% |
| Celularity Inc. | 102.92 Million USD | -41.718% |
| Omeros Corporation | 403.25 Million USD | 63.827% |
| Humacyte, Inc. | 114.67 Million USD | -27.2% |
| Immunocore Holdings plc | 228.15 Million USD | 36.067% |
| IO Biotech, Inc. | 17.55 Million USD | -730.878% |
| GT Biopharma, Inc. | 6.63 Million USD | -2099.141% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -735.83% |
| Summit Therapeutics Inc. | 125.25 Million USD | -16.456% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -7357.515% |
| Pulmatrix, Inc. | 15.96 Million USD | -813.794% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 41.84% |
| Evogene Ltd. | 17.99 Million USD | -710.834% |
| CorMedix Inc. | 11.91 Million USD | -1123.987% |
| BioLineRx Ltd. | 50.7 Million USD | -187.699% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -1457.265% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -2479.926% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 94.641% |
| scPharmaceuticals Inc. | 57.26 Million USD | -154.744% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -548.278% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -27.05% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1265.789% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -2107.702% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -224.406% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -4982.544% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -2045.132% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -112.09% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -674.827% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -212.093% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -1077.5% |
| Daré Bioscience, Inc. | 26.32 Million USD | -454.006% |
| bluebird bio, Inc. | 424.62 Million USD | 65.647% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 92.282% |
| DBV Technologies S.A. | 42.8 Million USD | -240.815% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -14.147% |
| Galecto, Inc. | 5.89 Million USD | -2374.033% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -1438.865% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -431.651% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 44.828% |
| GlycoMimetics, Inc. | 6.9 Million USD | -2013.408% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 42.275% |
| ADMA Biologics, Inc. | 193.97 Million USD | 24.8% |
| Clene Inc. | 38.95 Million USD | -274.494% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | 23.333% |
| Aptose Biosciences Inc. | 15.8 Million USD | -822.713% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -1221.315% |
| Soligenix, Inc. | 7.27 Million USD | -1905.099% |
| Century Therapeutics, Inc. | 175.94 Million USD | 17.092% |
| Kura Oncology, Inc. | 51.66 Million USD | -182.353% |
| Surrozen, Inc. | 8.14 Million USD | -1690.902% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -20.273% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -2105.506% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 42.253% |
| Autolus Therapeutics plc | 263.9 Million USD | 44.727% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -1291.614% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -211.028% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -101.013% |
| GRI Bio, Inc. | 2.69 Million USD | -5308.565% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -17917.75% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -304.54% |
| INmune Bio, Inc. | 18.86 Million USD | -673.349% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 43.126% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -447.519% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -5265.976% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -3967.146% |
| Jaguar Health, Inc. | 45.86 Million USD | -218.033% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -4346.865% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -149.541% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -192.147% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 44.9% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 82.277% |
| Verastem, Inc. | 71.18 Million USD | -104.915% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -278.114% |
| Histogen Inc. | 5.69 Million USD | -2460.453% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -3226.086% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 54.014% |
| Surrozen, Inc. | 8.14 Million USD | -1690.902% |
| Organovo Holdings, Inc. | 2.74 Million USD | -5208.188% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -46376.113% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -17540.998% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -15.107% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -1248.941% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -5494.542% |
| Kronos Bio, Inc. | 54.2 Million USD | -169.126% |
| Turnstone Biologics Corp. | 14.14 Million USD | -931.022% |
| Synaptogenix, Inc. | 5.52 Million USD | -2538.029% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -2094.179% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 35.693% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | 14.249% |
| Exelixis, Inc. | 678.44 Million USD | 78.5% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | 11.08% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 75.452% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -893.929% |
| ESSA Pharma Inc. | 3.49 Million USD | -4073.563% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -2766.569% |
| Avid Bioservices, Inc. | 275.66 Million USD | 47.085% |
| Insmed Incorporated | 1.66 Billion USD | 91.222% |
| MediWound Ltd. | 27.18 Million USD | -436.54% |
| OmniAb, Inc. | 87.4 Million USD | -66.898% |
| Alector, Inc. | 487.66 Million USD | 70.089% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 63.845% |
| Zai Lab Limited | 240.17 Million USD | 39.266% |
| AlloVir, Inc. | 45.01 Million USD | -224.045% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 76.848% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -376.727% |
| Aura Biosciences, Inc. | 29.22 Million USD | -399.09% |
| Immunic, Inc. | 25.36 Million USD | -475.012% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -110.684% |
| Veracyte, Inc. | 93.71 Million USD | -55.645% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -5474.598% |
| FibroGen, Inc. | 585.72 Million USD | 75.096% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -739.147% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -73.6% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -22235.685% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -2479.261% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -1679.324% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -73.608% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 94.429% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -406.103% |
| XBiotech Inc. | 8.39 Million USD | -1637.156% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -893.929% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -285.774% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -914.459% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -174.293% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 59.827% |
| Agenus Inc. | 462.29 Million USD | 68.447% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -442.587% |
| Theravance Biopharma, Inc. | 169 Million USD | 13.689% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 88.0% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 70.851% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 85.0% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -2318.611% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -11.917% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -39176.079% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -2730.193% |
| Lantern Pharma Inc. | 2.73 Million USD | -5224.304% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -243.423% |
| Ainos, Inc. | 7.39 Million USD | -1872.743% |
| Pluri Inc. | 34.11 Million USD | -327.618% |
| Prothena Corporation plc | 135.01 Million USD | -8.038% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 39.997% |
| Rallybio Corporation | 9.43 Million USD | -1445.877% |
| Kodiak Sciences Inc. | 213.59 Million USD | 31.706% |
| Cue Biopharma, Inc. | 24.44 Million USD | -496.723% |
| MeiraGTx Holdings plc | 319.99 Million USD | 54.415% |
| Annexon, Inc. | 47.11 Million USD | -209.582% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -51.36% |
| Moderna, Inc. | 4.57 Billion USD | 96.81% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -2892.185% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -90.082% |
| Blueprint Medicines Corporation | 918.64 Million USD | 84.121% |
| Immix Biopharma, Inc. | 3.72 Million USD | -3819.331% |
| CalciMedica, Inc. | 4.02 Million USD | -3521.375% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -17.159% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -69.977% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 35.866% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 47.49% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -824.802% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -187.223% |
| Nutriband Inc. | 1.07 Million USD | -13419.921% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -1271.852% |
| Vor Biopharma Inc. | 59.1 Million USD | -146.801% |
| Roivant Sciences Ltd. | 773.95 Million USD | 81.153% |
| Alkermes plc | 933.53 Million USD | 84.375% |
| ProKidney Corp. | 29.21 Million USD | -399.278% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -102.655% |
| Arcellx, Inc. | 339.75 Million USD | 57.066% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 92.278% |
| Tango Therapeutics, Inc. | 149.45 Million USD | 2.402% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -64.934% |
| Atai Life Sciences N.V. | 49.16 Million USD | -196.711% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -368.245% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -712.098% |
| MediciNova, Inc. | 3.89 Million USD | -3648.349% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -698.014% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -9597.183% |
| GeoVax Labs, Inc. | 3.51 Million USD | -4044.146% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 63.281% |
| Biomea Fusion, Inc. | 30.69 Million USD | -375.298% |
| RenovoRx, Inc. | 4.46 Million USD | -3166.211% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -367.514% |
| Geron Corporation | 146.12 Million USD | 0.177% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -665.797% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -354.959% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -97.681% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -66.74% |
| Royalty Pharma plc | 6.29 Billion USD | 97.684% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -331.948% |
| Imunon, Inc. | 8.53 Million USD | -1609.985% |
| BioAtla, Inc. | 48.98 Million USD | -197.777% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -11.688% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -926.163% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | 22.884% |
| Structure Therapeutics Inc. | 29.05 Million USD | -402.113% |
| 89bio, Inc. | 59.96 Million USD | -143.265% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -333.296% |
| aTyr Pharma, Inc. | 31.59 Million USD | -361.655% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -135.946% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -201.37% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -1688.045% |
| Akari Therapeutics, Plc | 4.58 Million USD | -3082.134% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -722.579% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 91.157% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -7.006% |
| Liquidia Corporation | 73.13 Million USD | -99.444% |
| Entera Bio Ltd. | 1.37 Million USD | -10477.883% |
| GH Research PLC | 6.7 Million USD | -2076.824% |
| Vericel Corporation | 127.7 Million USD | -14.223% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -280.035% |
| Xencor, Inc. | 283.55 Million USD | 48.558% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -4785.629% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -5265.976% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -3782.463% |
| Vaxcyte, Inc. | 167.44 Million USD | 12.888% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -295.555% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -40.895% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -36014.412% |
| Portage Biotech Inc. | 4.45 Million USD | -3177.955% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -9597.183% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -532.837% |
| OncoCyte Corporation | 49.29 Million USD | -195.892% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -3426.127% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -18191.151% |
| Purple Biotech Ltd. | 10 Million USD | -1357.961% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -487.353% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -2095.83% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | 10.502% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -2421.068% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -1101.161% |
| United Therapeutics Corporation | 1.18 Billion USD | 87.661% |
| HilleVax, Inc. | 78.9 Million USD | -84.857% |
| Silo Pharma, Inc. | 1.56 Million USD | -9195.341% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -10821.903% |
| Pharming Group N.V. | 244.07 Million USD | 40.236% |
| Tharimmune, Inc. | 1.81 Million USD | -7936.656% |
| Genprex, Inc. | 3.25 Million USD | -4382.473% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -578.745% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -437.885% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -203.755% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -70710.194% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -40583.256% |
| OKYO Pharma Limited | 7.42 Million USD | -1865.665% |
| Savara Inc. | 37.19 Million USD | -292.205% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -402.737% |
| Curis, Inc. | 57.61 Million USD | -153.192% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -272.117% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -600.653% |
| BeiGene, Ltd. | 2.23 Billion USD | 93.47% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -585.668% |
| Erasca, Inc. | 78.61 Million USD | -85.558% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -22161.512% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -22161.512% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -1985.332% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -8708.514% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -754.534% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -300.123% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -162.189% |
| Adicet Bio, Inc. | 37.12 Million USD | -292.966% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 76.385% |
| Aditxt, Inc. | 28.53 Million USD | -411.255% |
| Adagene Inc. | 45.16 Million USD | -222.938% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -80623.958% |
| Quantum-Si incorporated | 26.63 Million USD | -447.741% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -4694.477% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -26.886% |
| Compugen Ltd. | 55.77 Million USD | -161.531% |
| Generation Bio Co. | 171.63 Million USD | 15.01% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -1162.935% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -248.71% |
| Invivyd, Inc. | 51.71 Million USD | -182.074% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -58.593% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -2142.327% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -93.214% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -14186.876% |
| 2seventy bio, Inc. | 310.12 Million USD | 52.965% |
| Instil Bio, Inc. | 99.8 Million USD | -46.16% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -303.702% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -10603.295% |
| GeoVax Labs, Inc. | 3.51 Million USD | -4044.146% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -1097.644% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -1096.157% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -176.053% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 60.56% |
| Evaxion Biotech A/S | 17.61 Million USD | -727.979% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | 9.358% |
| Verve Therapeutics, Inc. | 153.18 Million USD | 4.777% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -575.476% |
| Cingulate Inc. | 10.36 Million USD | -1307.884% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -5204.327% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -291.154% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -487.022% |
| Clearmind Medicine Inc. | 3.61 Million USD | -3940.684% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -210.076% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -540.908% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -626.765% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 37.985% |
| ImmunityBio, Inc. | 1.09 Billion USD | 86.622% |
| Korro Bio, Inc. | 51.75 Million USD | -181.862% |
| Kineta, Inc. | 7.22 Million USD | -1919.787% |
| BioVie Inc. | 9.7 Million USD | -1403.474% |
| Codexis, Inc. | 49.94 Million USD | -192.053% |
| Celularity Inc. | 102.92 Million USD | -41.718% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -29.778% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -51.557% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -42157.108% |
| Cibus, Inc. | 206.11 Million USD | 29.23% |
| IN8bio, Inc. | 8.77 Million USD | -1562.893% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -62.907% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -965.593% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 94.397% |
| Eyenovia, Inc. | 19.78 Million USD | -637.447% |
| Puma Biotechnology, Inc. | 177.08 Million USD | 17.628% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -1799.089% |
| Elevation Oncology, Inc. | 34.28 Million USD | -325.497% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -505.291% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -1125.996% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 40.593% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -1425.348% |
| Moolec Science SA | 13.94 Million USD | -946.004% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -238.035% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -188.667% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -266.726% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -1649.658% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -49446.884% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -5828.954% |
| Humacyte, Inc. | 114.67 Million USD | -27.2% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -451.219% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -12096.405% |
| Genelux Corporation | 8.42 Million USD | -1632.411% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -2027.611% |
| Notable Labs, Ltd. | 4.42 Million USD | -3194.985% |
| Immunovant, Inc. | 48.95 Million USD | -197.965% |
| Quantum-Si incorporated | 26.63 Million USD | -447.741% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -4600.902% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -97.491% |
| Acasti Pharma Inc. | 11.55 Million USD | -1162.17% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -545.217% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -529.18% |
| PepGen Inc. | 34.63 Million USD | -321.209% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -1988.617% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1604.636% |
| Immuneering Corporation | 12 Million USD | -1114.729% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -46376.113% |
| Belite Bio, Inc | 4.21 Million USD | -3363.999% |
| XOMA Corporation | 145.58 Million USD | -0.199% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -5907.784% |
| Bionomics Limited | 10.15 Million USD | -1335.899% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -536.621% |
| uniQure N.V. | 624.01 Million USD | 76.624% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -80623.958% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | 14.287% |
| Forte Biosciences, Inc. | 3.66 Million USD | -3878.969% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -55877.942% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -2061.983% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -1799.089% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -739.147% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -1280.29% |
| Altimmune, Inc. | 16.54 Million USD | -781.863% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -2892.799% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -536.621% |
| Peak Bio, Inc. | 20.75 Million USD | -602.869% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -32.052% |
| Benitec Biopharma Inc. | 4.96 Million USD | -2839.722% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | 7.586% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -94.042% |
| Zura Bio Limited | 21.29 Million USD | -585.088% |
| PolyPid Ltd. | 17.46 Million USD | -735.064% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -94.042% |
| argenx SE | 444.95 Million USD | 67.217% |
| Immunome, Inc. | 28.65 Million USD | -408.999% |
| Verona Pharma plc | 58.84 Million USD | -147.904% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -907.87% |
| Shattuck Labs, Inc. | 14.85 Million USD | -881.688% |
| CervoMed Inc. | 2.59 Million USD | -5519.538% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -1045.328% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -1284.613% |
| Moolec Science SA | 13.94 Million USD | -946.004% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -6124.397% |
| Design Therapeutics, Inc. | 11.95 Million USD | -1120.049% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -1050.024% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -274.715% |
| Achilles Therapeutics plc | 19.08 Million USD | -664.232% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -540.908% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -905.231% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 63.649% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -349.201% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -1017.848% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -2676.87% |
| Beam Therapeutics Inc. | 478.38 Million USD | 69.508% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 63.345% |
| AEON Biopharma, Inc. | 159.88 Million USD | 8.769% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -435.732% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -461.877% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -1818.769% |
| NeurAxis, Inc. | 1.91 Million USD | -7526.184% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 25.477% |
| Lumos Pharma, Inc. | 13.33 Million USD | -994.045% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -518.404% |
| Palisade Bio, Inc. | 2.73 Million USD | -5225.63% |
| Nutriband Inc. | 1.07 Million USD | -13419.921% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | 24.049% |
| Neurogene Inc. | 36.54 Million USD | -299.105% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -5866.012% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -206.126% |
| Athira Pharma, Inc. | 30.05 Million USD | -385.308% |
| HCW Biologics Inc. | 15.05 Million USD | -869.104% |
| XOMA Corporation | 145.58 Million USD | -0.199% |
| Nektar Therapeutics | 267.04 Million USD | 45.377% |
| Arvinas, Inc. | 644.6 Million USD | 77.371% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -722.579% |
| Merus N.V. | 102.15 Million USD | -42.797% |
| Omega Therapeutics, Inc. | 146.35 Million USD | 0.329% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -53.353% |
| Rezolute, Inc. | 11.73 Million USD | -1143.131% |
| Clene Inc. | 38.95 Million USD | -274.494% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -5022.92% |
| BeyondSpring Inc. | 48.26 Million USD | -202.2% |
| Synlogic, Inc. | 32.89 Million USD | -343.438% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -898.214% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -8827.111% |
| Peak Bio, Inc. | 20.75 Million USD | -602.869% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -129.863% |
| Krystal Biotech, Inc. | 39.71 Million USD | -267.299% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 61.271% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -46.5% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -33609.322% |
| MannKind Corporation | 721.36 Million USD | 79.779% |
| Ikena Oncology, Inc. | 22.33 Million USD | -553.096% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -6892.761% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -42.186% |
| Gossamer Bio, Inc. | 249.14 Million USD | 41.453% |
| CohBar, Inc. | 1.03 Million USD | -14012.194% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -1264.665% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -665.797% |
| Legend Biotech Corporation | 589.93 Million USD | 75.274% |
| Mural Oncology plc | 37.92 Million USD | -284.594% |
| Disc Medicine, Inc. | 22.87 Million USD | -537.679% |
| Champions Oncology, Inc. | 28.03 Million USD | -420.31% |
| REGENXBIO Inc. | 262.22 Million USD | 44.373% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -4242.177% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1063.787% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -986.011% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -587.899% |
| Vaxart, Inc. | 34.02 Million USD | -328.711% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -615.421% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -411.249% |
| Cellectis S.A. | 249.57 Million USD | 41.553% |
| Longeveron Inc. | 5.33 Million USD | -2633.165% |
| Repare Therapeutics Inc. | 41.81 Million USD | -248.81% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 93.935% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -141.633% |
| Revolution Medicines, Inc. | 262.39 Million USD | 44.409% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -6823.066% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -1591.039% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -1136.073% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -938.731% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -6681.45% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 97.167% |
| Denali Therapeutics Inc. | 122.96 Million USD | -18.628% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -2521.236% |
| Veru Inc. | 32.81 Million USD | -344.55% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -2023.584% |
| Cingulate Inc. | 10.36 Million USD | -1307.884% |
| Passage Bio, Inc. | 39.26 Million USD | -271.527% |
| Context Therapeutics Inc. | 4.19 Million USD | -3379.936% |
| Exicure, Inc. | 8.54 Million USD | -1606.27% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -394.337% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -1291.083% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -561.808% |
| Nuvalent, Inc. | 31.82 Million USD | -358.376% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -2192.951% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -131.457% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -710.383% |
| OmniAb, Inc. | 87.4 Million USD | -66.898% |
| Anew Medical, Inc. | 8.24 Million USD | -1669.868% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -280.967% |
| Lipocine Inc. | 2.63 Million USD | -5442.917% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -455.226% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -262.75% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -447.519% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -69.312% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -2600.778% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -76.283% |
| Ocugen, Inc. | 23.98 Million USD | -508.218% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -214.325% |
| Q32 Bio Inc. | 233.12 Million USD | 37.43% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -1508.968% |
| Alumis Inc. Common Stock | 53.5 Million USD | -172.642% |
| Equillium, Inc. | 27.95 Million USD | -421.762% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 29.393% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -2492.459% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -2278.441% |
| Dominari Holdings Inc. | 4.63 Million USD | -3047.12% |
| Edesa Biotech, Inc. | 1.84 Million USD | -7820.616% |
| vTv Therapeutics Inc. | 29.56 Million USD | -393.351% |
| Bio-Techne Corporation | 744.34 Million USD | 80.403% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -15.678% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 57.652% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -259.505% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -403.743% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -57.935% |
| Nkarta, Inc. | 105.6 Million USD | -38.134% |
| BioCardia, Inc. | 4.59 Million USD | -3077.974% |
| Iterum Therapeutics plc | 32.66 Million USD | -346.602% |